Blood Pressure Optimisation Programme impact report (The AHSN Network, 29 June 2023)

Summary

The Covid-19 pandemic had an adverse impact on the detection and management of cardiovascular disease (CVD) risk factors including hypertension. In June 2022, nearly two million fewer people with hypertension were recorded as being treated to target, compared with the previous year. As a result, NHS England commissioned the AHSN Network to deliver a new national Blood Pressure Optimisation (BPO) programme building on its portfolio of work around cardiovascular disease. This report lays out:

• evidence about the impact of the BPO programme
• how it has been received by frontline staff
• how it has been implemented nationally.